Comparative evaluation of resectability, postoperative morbidity and mediastinal downstaging after cisplatin-based chemoinduction versus radiochemoinduction for stage III non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 214s Year: 2003
Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
Long-term follow-up comparing postoperative chemotherapy or radiotherapy and surgery with surgery alone in resectable nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 131s Year: 2001
Long-term survival after surgical resection for non-small cell lung cancer Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
The efficacy of induction chemoradiotherapy followed by surgery in stage IIIA-proven N2 NSCLC and the influence of lymph node downstage on the incidence of postoperative recurrence Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Chemotherapy plus resection is not better than chemoradiotherapy for baseline unresectable stage IIIA-N2 NSCLC Source: ISSN=ISSN 1810-6838, ISBN=, page=380 Year: 2007
Is there any survival benefit of surgery after neoadjuvant chemoradiotherapy and persisting pn2/3 in stage III NSCLC? Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009
Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005
The survival in elderly patients after resection of lung cancer Source: Annual Congress 2008 - Congenital lung lesions and emphysema; lung cancer surgery Year: 2008
Radical radiotherapy in medically inoperable early stage non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001
Contribution of FDG-PET on staging and management of NSCLC planned for concomitant chemoradiotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 664s Year: 2007
Improved overall survival after late recurrence of lung cancer following the introduction of CT-based follow-up for patients treated with curative intent Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies Year: 2018
Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Survival of patients after complete surgical resection in NSCLC stage IV with solitary metastases Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Trends in mediastinal nodal staging and its impact on unforeseen N2 and survival in lung cancer Source: Eur Respir J, 57 (4) 2001549; 10.1183/13993003.01549-2020 Year: 2021
Surgical treatment of lung cancer after polyhemothetapy/radiotherapy down-staging in patients initially assessed as inoperable Source: Eur Respir J 2006; 28: Suppl. 50, 718s Year: 2006